Reuben A Gittelman R, Gao J, Zhang J, Yusko E, Wu CJ, Emerson R, Chen R, Zhang J, Tipton C, Vence L, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, e P, Forget MA, Federico L, Haymaker C, Behren C, Benzeno S, Bernatchez C, Sepesi B, Gibbons D, Wargo J, Swisher SG , Heymach J, Robins H, Lee JJ, Sharma P, Allison J, Futreal PA, Wistuba I, Zhang J
Current evidence remains mixed and context-dependent, varying by tissue, genetics, and environmental exposures
Speaking specifically to your expertise in family medicine, what can families do to encourage healthy habits for all members
By now, it should not come as a surprise that GLP-1 agonists like semaglutide and tirzepetide could do this
U., Patel, A
Summary Microdosing is typically treated as a tolerability-first, clinician-guided approach, involving starts below the usual 2.5 mg step, extending escalation windows from 4 to 8 weeks or more, or pausing at intermediate maintenance doses, such as 5 mg or 7.5 mg, to prioritize steady adherence and symptom control